Related Experiment Videos
Novel reverse-turn mimics inhibit farnesyl transferase
1Cold Spring Harbor Laboratory, NY 11724, USA.
Bioorganic & Medicinal Chemistry Letters
|April 17, 1999
Summary
New bicyclic lactam peptides inhibit RAS farnesylation, a key process in cell signaling. The Fmoc-protected versions effectively block RAS transformation, offering potential therapeutic strategies.
Area of Science:
- Biochemistry
- Organic Chemistry
- Molecular Biology
Background:
- RAS farnesylation is a critical post-translational modification for RAS protein function.
- Inhibiting RAS farnesylation is a potential strategy for cancer therapy.
- Bicyclic lactams can induce reverse turns, influencing peptide structure and function.
Purpose of the Study:
- To design and synthesize novel inhibitors of RAS farnesylation.
- To investigate the effect of incorporating reverse-turn inducing bicyclic lactams into peptide substrates of farnesyl transferase.
- To evaluate the inhibitory potential of these modified peptides against RAS farnesylation.
Main Methods:
- Synthesis of Fmoc-protected bicyclic lactam peptides.
- Incorporation of these peptides into the substrate sequence for farnesyl transferase.
- Assay of farnesyl transferase activity with modified peptides.
- Determination of IC50 values for inhibition.
Main Results:
- Free bicyclic lactam peptides showed no significant inhibition of farnesyl transferase.
- Fmoc-protected bicyclic lactam peptides effectively inhibited RAS farnesylation.
- The IC50 values for inhibition were in the low micromolar range.
Conclusions:
- Reverse-turn inducing bicyclic lactams can be successfully incorporated into peptide substrates to create potent inhibitors of RAS farnesylation.
- Fmoc-protected bicyclic lactam peptides represent a promising class of compounds for targeting RAS-mediated signaling pathways.
- These findings support the development of novel anti-cancer therapeutics targeting farnesyl transferase.